| Dr Gregory Gerard Decandia, MD | |
|
1461 South Britain Road, Southbury, CT 06488-0901 | |
| (203) 586-2000 | |
| Not Available |
| Full Name | Dr Gregory Gerard Decandia |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 1461 South Britain Road, Southbury, Connecticut |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003890641 | NPI | - | NPPES |
| 3128075 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 76773 (Massachusetts) | Secondary |
| 207Q00000X | Family Medicine | 029717 (Connecticut) | Primary |
| Entity Name | Genesis Eldercare Physician Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164415196 PECOS PAC ID: 9830002534 Enrollment ID: O20031110000130 |
News Archive
The U.S. Food and Drug Administration today approved a device that measures glucose levels continuously for up to seven days in people with diabetes.
Current treatments for asthma and chronic bronchitis aren't able to address the ultimate source of the problem-they can only alleviate symptoms.
Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for the treatment of diffuse large B cell lymphoma (DLBCL).
Research conducted at Texas A&M University casts doubts on the notion that El Ni-o has been getting stronger because of global warming and raises interesting questions about the relationship between El Ni-o and a severe flu pandemic 91 years ago. The findings are based on analysis of the 1918 El Ni-o, which the new research shows to be one of the strongest of the 20th century.
› Verified 9 days ago
| Entity Name | State Of Connecticut |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467582072 PECOS PAC ID: 8022915677 Enrollment ID: O20031212000803 |
News Archive
The U.S. Food and Drug Administration today approved a device that measures glucose levels continuously for up to seven days in people with diabetes.
Current treatments for asthma and chronic bronchitis aren't able to address the ultimate source of the problem-they can only alleviate symptoms.
Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for the treatment of diffuse large B cell lymphoma (DLBCL).
Research conducted at Texas A&M University casts doubts on the notion that El Ni-o has been getting stronger because of global warming and raises interesting questions about the relationship between El Ni-o and a severe flu pandemic 91 years ago. The findings are based on analysis of the 1918 El Ni-o, which the new research shows to be one of the strongest of the 20th century.
› Verified 9 days ago
| Entity Name | State Of Connecticut |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720013360 PECOS PAC ID: 8022915677 Enrollment ID: O20040319000785 |
News Archive
The U.S. Food and Drug Administration today approved a device that measures glucose levels continuously for up to seven days in people with diabetes.
Current treatments for asthma and chronic bronchitis aren't able to address the ultimate source of the problem-they can only alleviate symptoms.
Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for the treatment of diffuse large B cell lymphoma (DLBCL).
Research conducted at Texas A&M University casts doubts on the notion that El Ni-o has been getting stronger because of global warming and raises interesting questions about the relationship between El Ni-o and a severe flu pandemic 91 years ago. The findings are based on analysis of the 1918 El Ni-o, which the new research shows to be one of the strongest of the 20th century.
› Verified 9 days ago
| Entity Name | Gps Physician Group, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881109452 PECOS PAC ID: 9739447400 Enrollment ID: O20180206000646 |
News Archive
The U.S. Food and Drug Administration today approved a device that measures glucose levels continuously for up to seven days in people with diabetes.
Current treatments for asthma and chronic bronchitis aren't able to address the ultimate source of the problem-they can only alleviate symptoms.
Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for the treatment of diffuse large B cell lymphoma (DLBCL).
Research conducted at Texas A&M University casts doubts on the notion that El Ni-o has been getting stronger because of global warming and raises interesting questions about the relationship between El Ni-o and a severe flu pandemic 91 years ago. The findings are based on analysis of the 1918 El Ni-o, which the new research shows to be one of the strongest of the 20th century.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gregory Gerard Decandia, MD 1461 South Britain Road/ P.o. Box 872, Southbury, CT 06488-0901 Ph: (203) 586-2000 | Dr Gregory Gerard Decandia, MD 1461 South Britain Road, Southbury, CT 06488-0901 Ph: (203) 586-2000 |
News Archive
The U.S. Food and Drug Administration today approved a device that measures glucose levels continuously for up to seven days in people with diabetes.
Current treatments for asthma and chronic bronchitis aren't able to address the ultimate source of the problem-they can only alleviate symptoms.
Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced that the U.S. Food and Drug Administration Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for the treatment of diffuse large B cell lymphoma (DLBCL).
Research conducted at Texas A&M University casts doubts on the notion that El Ni-o has been getting stronger because of global warming and raises interesting questions about the relationship between El Ni-o and a severe flu pandemic 91 years ago. The findings are based on analysis of the 1918 El Ni-o, which the new research shows to be one of the strongest of the 20th century.
› Verified 9 days ago
Dr. Agata Jaskiewicz-poznanska, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 22 Old Waterbury Rd, Southbury, CT 06488 Phone: 203-262-4200 | |
Dr. Kornelia Thomas, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 30 Quaker Farms Rd Ste 1, Southbury, CT 06488 Phone: 203-262-9300 Fax: 203-264-2696 | |
Mrs. Marianne Bette, MD EAAFP Family Medicine Medicare: Medicare Enrolled Practice Location: 77 Main Street North, Southbury, CT 06488 Phone: 203-267-5560 Fax: 203-267-5561 | |
Maria Lementowska, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1461 South Britain Rd, Southbury, CT 06488 Phone: 203-586-2000 Fax: 203-586-2701 | |
Robert Carr, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 22 Old Waterbury Rd, Southbury, CT 06488 Phone: 203-262-4200 | |
Dr. Andrew L Rubman, N.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 900 Main St S, Southbury, CT 06488 Phone: 203-262-6755 |